WMAHSN is looking for a Medicines Safety Leadfor its Medicines Optimisation and Management programme, due to AHSN funding this will be offered as a 12 month fixed term contract.
West Midlands Academic Health Science Network (WMAHSN) is one of 15 regional AHSNs licensed by NHS England with the purpose of spreading the adoption of innovation at scale and pace to improve health and wellbeing, and to deliver economic benefits. WMAHSN is hosted by UHB NHS Foundation NHS Trust.
By catalysing partnerships between the health and care sector, academia, business and patients, citizens and the third sector, WMAHSN identifies innovations that address the health needs of the region’s population, drive down costs and attract investment andjobsinto the West Midlands. Programmes of work are established to take the most attractive innovations forward to accelerate their uptake regionally, nationally and internationally.
One of the AHSN’s strategic priorities is medicines optimisation and management with an emphasis on sustaining the achievements to date in the delivery of PINCER, Transfer of Care around Medicines, electronic repeat dispensing and medicines administration in care homes. The priority encompasses programmes, projects, events and meetings involving a large and diverse range of organisations and individuals. The ambition is to support organisations and individuals with the infrastructure and capability to improve unnecessary prescribing, reduce prescribing errors and support the interface between secondary and primary care – improving quality, patient safety and experience whilst reducing costs.
The core requirement for the Medicines Safety Lead is to provide clinical advice and guidance along with operational support to the medicines safety priority with the planning, delivery and operational oversight ensuring the programmes deliver against the objectives of the national Medicines Safety Improvement Plan (MedsSIP). The need is to develop and implement a medicines safety programme initially focussing on safety administration of medicines in care homes and reducing inappropriate high dose opiate prescriptions for non-cancer patients. There will also be a requirement to support the wider medicines optimisation programme to reduce inappropriate polypharmacy and linking in with the CVD programme to explore the safer use of anticoagulants.
We are looking for a pharmacist with a background in medicines safety who can help develop this necessary and exciting programme of work. For further information please contact Jodie Mazur.